GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gufic Biosciences Ltd (NSE:GUFICBIO) » Definitions » Price-to-Owner-Earnings

Gufic Biosciences (NSE:GUFICBIO) Price-to-Owner-Earnings : (As of Jun. 02, 2025)


View and export this data going back to 2004. Start your Free Trial

What is Gufic Biosciences Price-to-Owner-Earnings?

As of today (2025-06-02), Gufic Biosciences's share price is ₹391.00. Gufic Biosciences does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Gufic Biosciences's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of Gufic Biosciences was 1131.34. The lowest was 12.73. And the median was 25.18.


NSE:GUFICBIO's Price-to-Owner-Earnings is not ranked *
in the Drug Manufacturers industry.
Industry Median: 25.185
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2025-06-02), Gufic Biosciences's share price is ₹391.00. Gufic Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was ₹8.17. Therefore, Gufic Biosciences's PE Ratio (TTM) for today is 47.86.

As of today (2025-06-02), Gufic Biosciences's share price is ₹391.00. Gufic Biosciences's EPS without NRI for the trailing twelve months (TTM) ended in was ₹8.34. Therefore, Gufic Biosciences's PE Ratio without NRI for today is 46.89.

During the past 13 years, Gufic Biosciences's highest PE Ratio without NRI was 108.13. The lowest was 13.95. And the median was 36.09.


Gufic Biosciences Price-to-Owner-Earnings Historical Data

The historical data trend for Gufic Biosciences's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gufic Biosciences Price-to-Owner-Earnings Chart

Gufic Biosciences Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.18 15.62 20.63 - -

Gufic Biosciences Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Gufic Biosciences's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Gufic Biosciences's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gufic Biosciences's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gufic Biosciences's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Gufic Biosciences's Price-to-Owner-Earnings falls into.


;
;

Gufic Biosciences Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Gufic Biosciences's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=391.00/-6.33
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gufic Biosciences  (NSE:GUFICBIO) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Gufic Biosciences Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Gufic Biosciences's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Gufic Biosciences Business Description

Traded in Other Exchanges
Address
SM House, 11 Sahakar Road, 1st to 4th Floor, Vile Parle (East), Mumbai, MH, IND, 400 057
Gufic Biosciences Ltd is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Geographically, it derives a majority of revenue from India. Its product portfolio includes Criticare; Criticare Life; Ferticare; Spark; Herbal and other products. The company's lyophilized product includes antibiotics, anti-fungal, cardiac, infertility, anti-viral and a proton-pump inhibitor. It derives maximum revenue from India.

Gufic Biosciences Headlines

No Headlines